Langbahn Team – Weltmeisterschaft

Adarigiline

Adarigiline
Clinical data
Drug classMonoamine oxidase B (MAO-B) inhibitor
Identifiers
  • (4-hydroxypiperidin-1-yl)-[5-[4-methyl-5-(trifluoromethyl)-1,2-oxazol-3-yl]thiophen-2-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H15F3N2O3S
Molar mass360.35 g·mol−1
3D model (JSmol)
  • CC1=C(ON=C1C2=CC=C(S2)C(=O)N3CCC(CC3)O)C(F)(F)F
  • InChI=1S/C15H15F3N2O3S/c1-8-12(19-23-13(8)15(16,17)18)10-2-3-11(24-10)14(22)20-6-4-9(21)5-7-20/h2-3,9,21H,4-7H2,1H3
  • Key:VXBWTNLAIBIATJ-UHFFFAOYSA-N

Adarigiline (INNTooltip International Nonproprietary Name) is a monoamine oxidase inhibitor (MAOI) that was never marketed.[1][2][3][4] It is specifically a monoamine oxidase B (MAO-B) inhibitor.[1][2][3] This drug candidate was first described in 2009, in a patent assigned to Helicon Therapeutics.[5]

References

  1. ^ a b "-giline MAO-inhibitors type B C.3.1.0 (a) adarigiline (117),clorgiline (23), mofegiline (69), pargyline (13), rasagiline (70), selegiline (39), sembragiline (111)". Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (Stem book 2024) (PDF). World Health Organization. 2024. p. 112. ISBN 978-92-4-009938-8.
  2. ^ a b "Proposed INN: List 117 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 31 (2). 2017. tadarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone monoamine oxidase B inhibitor [...] C15H15F3N2O3S 1124197-79-0
  3. ^ a b "Recommended INN: List 79 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 32 (1). 2018. adarigilinum adarigiline (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)- 1,2-oxazol-3-yl]thiophen-2-yl}methanone [...] C15H15F3N2O3S
  4. ^ "ADARIGILINE". Inxight Drugs. Retrieved 24 February 2025.
  5. ^ WO 2009/029632A1, Kaplan AP, Keenan TP, Mcriner AJ, "Therapeutic isoxazole compounds", published 5 March 2009, assigned to Helicon Therapeutics, Inc. 
Quelle: http://en.wikipedia.org/wiki/Adarigiline